vida: extract claims from 2025-01-29-pmc-oregon-psilocybin-facilitator-workforce-survey

- Source: inbox/queue/2025-01-29-pmc-oregon-psilocybin-facilitator-workforce-survey.md
- Domain: health
- Claims: 2, Entities: 0
- Enrichments: 2
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/oregon-psilocybin-access-gap-is-demand-side-cost-failure-not-supply-side-capacity-constraint.md

@@ -0,0 +1,19 @@
+---
+type: claim
+domain: health
+description: Oregon's psilocybin program has facilitator supply exceeding demand by 13x, inverting the typical healthcare access narrative where provider shortage is the binding constraint
+confidence: experimental
+source: Journal of Psychoactive Drugs PMC12304229, Oregon facilitator survey N=106, 2023-2025 data
+created: 2026-05-11
+title: Oregon's psilocybin access gap is a demand-side cost failure, not a supply-side capacity problem — facilitators have capacity for 60,000 clients/year but only 4,500/year are being served because session costs ($1,200-3,000) are uninsured and out-of-pocket
+agent: vida
+sourced_from: health/2025-01-29-pmc-oregon-psilocybin-facilitator-workforce-survey.md
+scope: structural
+sourcer: Journal of Psychoactive Drugs
+challenges: ["the-mental-health-supply-gap-is-widening-not-closing-because-demand-outpaces-workforce-growth-and-technology-primarily-serves-the-already-served-rather-expanding-access"]
+related: ["glp-1-access-structure-inverts-need-creating-equity-paradox", "the-mental-health-supply-gap-is-widening-not-closing-because-demand-outpaces-workforce-growth-and-technology-primarily-serves-the-already-served-rather-expanding-access", "psilocybin-achieves-positive-phase3-trd-single-dose-26week-durability"]
+---
+
+# Oregon's psilocybin access gap is a demand-side cost failure, not a supply-side capacity problem — facilitators have capacity for 60,000 clients/year but only 4,500/year are being served because session costs ($1,200-3,000) are uninsured and out-of-pocket
+
+Oregon licensed approximately 500 psilocybin facilitators by Q1 2026, each with capacity to serve ~10 clients/month (mean intended monthly clients from survey). This creates theoretical capacity of 60,000 clients/year. However, Oregon's actual utilization in Q1 2025 was 1,509 clients in 4 months, projecting to ~4,500 clients/year — only 7.5% of facilitator capacity. Survey respondents planned to charge mean $1,388 per session, below current market rates of $1,500-3,000, yet utilization remains extremely low. This demonstrates that Oregon's psilocybin access gap is NOT a supply-side capacity constraint (the facilitators exist and have availability) but a demand-side affordability problem — sessions are uninsured, out-of-pocket, and cost-prohibitive for most potential users. This inverts the typical healthcare access narrative where provider shortage is the binding constraint. The policy implication: scaling access requires reimbursement infrastructure, not more facilitator training programs.

domains/health/psilocybin-achieves-positive-phase3-trd-single-dose-26week-durability.md

@@ -10,18 +10,18 @@ agent: vida
 sourced_from: health/2025-06-23-compass-pathways-comp005-psilocybin-phase3-trd.md
 scope: causal
 sourcer: Compass Pathways
-challenges:
-- prescription-digital-therapeutics-failed-as-a-business-model-because-fda-clearance-creates-regulatory-cost-without-the-pricing-power-that-justifies-it-for-near-zero-marginal-cost-software
-related:
-- the-mental-health-supply-gap-is-widening-not-closing-because-demand-outpaces-workforce-growth-and-technology-primarily-serves-the-already-served-rather-than-expanding-access
-- prescription-digital-therapeutics-failed-as-a-business-model-because-fda-clearance-creates-regulatory-cost-without-the-pricing-power-that-justifies-it-for-near-zero-marginal-cost-software
-- antidepressant-discontinuation-follows-continuous-treatment-model-but-psychological-support-mitigates-relapse
-supports:
-- Trump's April 2026 Executive Order on psychedelics represents the first federal bipartisan commitment to Schedule I psychedelic drug development pathways, signaling regulatory environment shift that de-risks clinical investment through existing frameworks rather than new legislation
-reweave_edges:
-- Trump's April 2026 Executive Order on psychedelics represents the first federal bipartisan commitment to Schedule I psychedelic drug development pathways, signaling regulatory environment shift that de-risks clinical investment through existing frameworks rather than new legislation|supports|2026-05-11
+challenges: ["prescription-digital-therapeutics-failed-as-a-business-model-because-fda-clearance-creates-regulatory-cost-without-the-pricing-power-that-justifies-it-for-near-zero-marginal-cost-software"]
+related: ["the-mental-health-supply-gap-is-widening-not-closing-because-demand-outpaces-workforce-growth-and-technology-primarily-serves-the-already-served-rather-than-expanding-access", "prescription-digital-therapeutics-failed-as-a-business-model-because-fda-clearance-creates-regulatory-cost-without-the-pricing-power-that-justifies-it-for-near-zero-marginal-cost-software", "antidepressant-discontinuation-follows-continuous-treatment-model-but-psychological-support-mitigates-relapse", "psilocybin-achieves-positive-phase3-trd-single-dose-26week-durability", "psychedelic-therapy-regulatory-success-requires-active-comparator-or-objective-endpoints-for-highly-psychoactive-compounds"]
+supports: ["Trump's April 2026 Executive Order on psychedelics represents the first federal bipartisan commitment to Schedule I psychedelic drug development pathways, signaling regulatory environment shift that de-risks clinical investment through existing frameworks rather than new legislation"]
+reweave_edges: ["Trump's April 2026 Executive Order on psychedelics represents the first federal bipartisan commitment to Schedule I psychedelic drug development pathways, signaling regulatory environment shift that de-risks clinical investment through existing frameworks rather than new legislation|supports|2026-05-11"]
 ---
 
 # Psilocybin achieves positive Phase 3 evidence for treatment-resistant depression with single-dose 26-week durability representing the first FDA-approvable psychedelic
 
-The COMP005 trial achieved its primary endpoint with a statistically significant MADRS improvement of -3.6 points versus placebo (95% CI [-5.7, -1.5], p<0.001) at week 6 in 258 participants with treatment-resistant depression. The effect size is comparable to existing TRD augmentation strategies (typically 2-4 MADRS points) but with a fundamentally different dosing paradigm: a single administration producing benefits that persist through 26 weeks. This durability from a single dose represents a paradigm shift from the daily-dosing chronic treatment model that defines current psychiatric pharmacotherapy. The trial embedded psychological support as a required protocol component (preparation, session monitoring, integration), indicating that psilocybin therapy is a hybrid clinical intervention combining pharmacological mechanism (5-HT2A agonism) with structured psychological process. Safety profile showed all adverse events were mild-to-moderate and resolved within 24 hours, with no clinically meaningful difference in suicidal ideation between arms. This is the first investigational psychedelic to report positive Phase 3 data, establishing proof-of-concept for FDA approval of a classic psychedelic and creating a regulatory pathway for the broader class. The treatment-resistant depression population (7M Americans who have failed 2+ antidepressant courses) represents a clinical need where existing medicine has limited options, making this a genuine expansion of the treatment toolkit rather than incremental improvement.
+The COMP005 trial achieved its primary endpoint with a statistically significant MADRS improvement of -3.6 points versus placebo (95% CI [-5.7, -1.5], p<0.001) at week 6 in 258 participants with treatment-resistant depression. The effect size is comparable to existing TRD augmentation strategies (typically 2-4 MADRS points) but with a fundamentally different dosing paradigm: a single administration producing benefits that persist through 26 weeks. This durability from a single dose represents a paradigm shift from the daily-dosing chronic treatment model that defines current psychiatric pharmacotherapy. The trial embedded psychological support as a required protocol component (preparation, session monitoring, integration), indicating that psilocybin therapy is a hybrid clinical intervention combining pharmacological mechanism (5-HT2A agonism) with structured psychological process. Safety profile showed all adverse events were mild-to-moderate and resolved within 24 hours, with no clinically meaningful difference in suicidal ideation between arms. This is the first investigational psychedelic to report positive Phase 3 data, establishing proof-of-concept for FDA approval of a classic psychedelic and creating a regulatory pathway for the broader class. The treatment-resistant depression population (7M Americans who have failed 2+ antidepressant courses) represents a clinical need where existing medicine has limited options, making this a genuine expansion of the treatment toolkit rather than incremental improvement.
+
+## Extending Evidence
+
+**Source:** Journal of Psychoactive Drugs PMC12304229, Oregon facilitator workforce survey 2023-2025
+
+Oregon's real-world implementation shows facilitators specializing in trauma (83%), mental health disorders (69%), and consciousness exploration (68%), with mean planned session cost of $1,388 — below current market of $1,500-3,000 but still unaffordable for most potential TRD patients without insurance coverage. The 7.5% capacity utilization (4,500 actual vs 60,000 theoretical clients/year) demonstrates that clinical efficacy alone is insufficient for population-level access.

domains/health/psilocybin-facilitator-training-costs-create-economic-filtering-toward-already-credentialed-healthcare-workers-despite-equity-intentions.md

@@ -0,0 +1,19 @@
+---
+type: claim
+domain: health
+description: High training barriers reproduce healthcare workforce stratification even in a new therapeutic modality designed for accessibility
+confidence: experimental
+source: Journal of Psychoactive Drugs PMC12304229, Oregon facilitator survey N=106
+created: 2026-05-11
+title: "Psilocybin facilitator training costs ($9,359 mean, 160+ hours) create economic filtering toward already-credentialed healthcare workers despite program equity intentions, with 79% reporting moderate-to-severe financial strain and 57% already holding healthcare licenses"
+agent: vida
+sourced_from: health/2025-01-29-pmc-oregon-psilocybin-facilitator-workforce-survey.md
+scope: structural
+sourcer: Journal of Psychoactive Drugs
+supports: ["the-mental-health-supply-gap-is-widening-not-closing-because-demand-outpaces-workforce-growth-and-technology-primarily-serves-the-already-served-rather-expanding-access"]
+related: ["glp-1-access-structure-inverts-need-creating-equity-paradox"]
+---
+
+# Psilocybin facilitator training costs ($9,359 mean, 160+ hours) create economic filtering toward already-credentialed healthcare workers despite program equity intentions, with 79% reporting moderate-to-severe financial strain and 57% already holding healthcare licenses
+
+Oregon's psilocybin facilitator training programs charge $4,500-$12,000 tuition (mean $9,359) for 120-200 hours of coursework plus 40-hour practicum, typically spanning 8 months. Despite 50% of programs offering scholarships for equity/inclusion, 79% of trainees reported the training costs created moderate-to-severe financial strain. The resulting workforce shows economic filtering: 72.5% hold graduate degrees, 57.3% already possess healthcare credentials, and mean age is 42.8 years — indicators of established professional status. While the workforce is racially diverse (35.6% people of color, exceeding the 12.5% client POC representation), the economic barriers filter toward people who already have financial resources and professional credentials. This creates a structural equity paradox: the program attracts diverse trainees but the cost barrier ensures they come from economically privileged backgrounds. The training pipeline itself reproduces healthcare workforce stratification even in a therapeutic modality explicitly designed for broader accessibility.

domains/health/psilocybin-therapy-requires-psychological-support-as-embedded-protocol-component.md

@@ -11,9 +11,16 @@ sourced_from: health/2025-06-23-compass-pathways-comp005-psilocybin-phase3-trd.m
 scope: structural
 sourcer: Compass Pathways
 supports: ["behavioral-biological-health-dichotomy-false-for-reward-dysregulation-conditions"]
-related: ["cognitive-behavioral-therapy-provides-durable-relapse-protection-through-skill-acquisition-unlike-pharmacological-interventions", "behavioral-biological-health-dichotomy-false-for-reward-dysregulation-conditions"]
+related: ["cognitive-behavioral-therapy-provides-durable-relapse-protection-through-skill-acquisition-unlike-pharmacological-interventions", "behavioral-biological-health-dichotomy-false-for-reward-dysregulation-conditions", "psilocybin-therapy-requires-psychological-support-as-embedded-protocol-component", "psychedelic-therapy-regulatory-success-requires-active-comparator-or-objective-endpoints-for-highly-psychoactive-compounds", "psilocybin-achieves-positive-phase3-trd-single-dose-26week-durability"]
 ---
 
 # Psilocybin therapy requires psychological support as an embedded clinical protocol component not an optional adjunct
 
 The COMP005 trial embedded psychological support as a mandatory protocol component across three phases: pre-session preparation, monitored dosing session (with trained facilitators present throughout the 6-8 hour experience), and post-session integration sessions. This design choice indicates that psilocybin therapy is not purely pharmacological but rather a hybrid intervention where the drug enables a psychological process that requires professional support to translate into clinical benefit. The trial's positive results cannot be attributed to the molecule alone but rather to the complete protocol package. This has significant implications for clinical implementation: psilocybin therapy will require specialized training infrastructure, dedicated session spaces, and multi-hour clinician time per patient—creating a fundamentally different delivery model than traditional psychiatric pharmacotherapy. The psychological support requirement also creates a natural quality control mechanism that may prevent the commoditization pathway seen with other psychiatric medications. This sits at the clinical/non-clinical interface: the pharmacological mechanism (5-HT2A agonism, neuroplasticity) is necessary but not sufficient; the psychological meaning-making process enabled by the drug state appears essential for durable benefit. The FDA approval pathway will need to specify not just the molecule but the complete therapeutic protocol, creating precedent for regulating hybrid pharmacological-psychological interventions.
+
+
+## Supporting Evidence
+
+**Source:** Journal of Psychoactive Drugs PMC12304229, Oregon facilitator training and practice parameters
+
+Oregon facilitator training requires 120-200 hours coursework plus 40-hour practicum, with facilitators planning mean 18.6 hours/week service delivery for ~10 clients/month. This infrastructure investment confirms psychological support is not optional but structurally embedded in the legal psilocybin service model.

inbox/archive/health/2025-01-29-pmc-oregon-psilocybin-facilitator-workforce-survey.md

@@ -7,10 +7,13 @@ date: 2025-01-29
 domain: health
 secondary_domains: []
 format: peer-reviewed
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-05-11
 priority: high
 tags: [psilocybin, Oregon, facilitator-workforce, scalability, access, training, equity]
 intake_tier: research-task
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content